Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced additional positive results from its Phase III program for NEBIDO (testosterone undecanoate), a long-acting injectable testosterone therapy under development for the treatment of male hypogonadism. The trial data announced has been filed with the U.S. Food and Drug Administration (FDA) as an addition to data contained in the Company’s existing New Drug Application (NDA) that was originally filed on August 28, 2007.

More: continued here

This entry was posted on Tuesday, January 29th, 2008 at 3:01 pm and is filed under Endocrinology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.